Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on May 19, 2026. The filing discloses initial clinical data from the Phase 2 ReInspire trial of zovegalisib for the treatment of vascular anomalies driven by PIK3CA mutations. The data cut-off date for the reported results was April 15, 2026.
Key Clinical Metrics and Outcomes
The filing focuses on clinical efficacy, safety, and patient-reported outcomes rather than financial metrics. Key data points include:
- Study Population: 32 patients enrolled and randomized (12 years or older) across three dose cohorts: 100mg BID (N=11), 300mg BID (N=11), and 400mg BID (N=10). Indications included PIK3CA-related overgrowth spectrum (PROS), lymphatic malformation (LM), and venous malformation (VeM).
- Efficacy (Volumetric Response): Of 20 response-evaluable patients, 60% achieved a volumetric response (defined as ≥20% reduction in target lesion volume). Post cut-off data updated the overall volumetric response rate to 65% (13/20).
- Dose-Specific Response: The 300mg BID and 100mg BID cohorts showed a combined response rate of 69% (9/13). The 100mg BID cohort specifically showed a 43% response rate (3/7).
- Patient-Reported Outcomes: At week 12, 89% of patients showed clinical improvement per Investigator Global Impression of Change (IGIC), 79% per Patient Global Impression of Change (PGIC), and 71% showed improvement in pain scores (IADRSS).
- Safety and Tolerability: Among patients treated at 100mg and 300mg BID, only 9% (2 patients) experienced Grade 3+ treatment-related adverse events. No rash, stomatitis, Grade 3 hyperglycemia, or diarrhea was observed. The 400mg BID dose was deprioritized due to a suboptimal safety profile.
Material Changes and Observations
The filing represents a significant milestone in the development of zovegalisib for vascular anomalies. Notable observations include:
- Response Durability: Four patients with 24-week scans confirmed their response with deepening reduction of lesion volume.
- Prior Treatment Impact: Responses were observed in patients previously treated with alpelisib and/or sirolimus (62% response rate in this subgroup).
- Dose Optimization: The data supports dose optimization for chronic treatment, with the 400mg BID dose deemed unsuitable for this specific patient population.
Outlook, Risks, and Forward-Looking Statements
Management indicated that the safety profile is consistent with mutant-selective PI3Kα inhibition. The company is proceeding with dose optimization to identify go-forward doses. The filing includes standard forward-looking statements regarding the potential commercialization of zovegalisib, the execution of Phase 3 trials (ReDiscover-2 and frontline readiness activities), and regulatory interactions.
Risks and Contingencies: The company highlights risks associated with global economic uncertainty, geopolitical instability, clinical trial delays, and the possibility that interim data may not be predictive of final results. The company explicitly disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) for detailed statistical analysis not summarized here.
- Confirm the specific mutation types (kinase vs. non-kinase) associated with the responding patients to assess biomarker efficacy.
- Monitor upcoming announcements regarding the selection of the go-forward dose for chronic treatment based on the 100mg and 300mg BID data.
- Review the company's most recent Form 10-K and 10-Q for detailed financial liquidity, cash burn, and debt positions, as this 8-K does not contain financial statements.
- Track regulatory interactions regarding the Phase 3 ReDiscover-2 trial and the potential frontline Phase 3 trial design.